Neptazane  (U.S.N.L.M.) | ||
---|---|---|
Dosing | 50mg po single dose for emergency IOP reduction (See package insert for other dosing.) |
|
Chem Specs | methazolamide | |
Quantities | 25,  50mg tab | |
Cost | 248.80/30tab/50mg (generic) | |
Class | carbonic anhydrase inhibitor | |
Action | Inhibition of carbonic anhydrase II in the ciliary processes presumably slows the formation of bicarbonate with subsequent reduction in sodium and fluid transport. Inhibition of carbonic anhydrase II in the ciliary processes presumably slows the formation of bicarbonate with subsequent reduction in sodium and fluid transport. |
|
Usage | Indicated in the treatment of chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma Indicated in the treatment of chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma |
|
Sulfonamides1 can cause hypersensitivity fatalities, Stevens-Johnson
syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Sulfonamides1 can cause hypersensitivity fatalities, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis,aplastic anemia and other blood dyscrasias. |
||
Contraindications | Low sodium and/or potassium serum levels, marked kidney or liver disease or dysfunction, adrenal gland failure, and hyperchloremic acidosis. In patients with cirrhosis, use may precipitate the development of hepatic encephalopathy. Hypersensitivity to any component of this product. Low sodium and/or potassium serum levels, marked kidney or liver disease or dysfunction, adrenal gland failure, and hyperchloremic acidosis. In patients with cirrhosis, use may precipitate the development of hepatic encephalopathy. Hypersensitivity to any component of this product. |
|
Pediatric use | Safety and effectiveness in children not established. | |
Pregnancy | Category C. Teratogenic in rats when given in doses 40 times the human dose. | |
Anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors. Anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors. |
||
"Life Threatening allergic reaction" based on the absence of the arylamine of sulfonamides and the relatively low rate of reported incidents.
https://link.springer.com/article/10.1007/s40123-018-0136-8 N.L.M. DailyMed page for Lumigan